Literaturverzeichnis

Acta Psychiatrica Scandinavia, 1987 The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987, 334 Suppl . , S.1-100,

Agúndez et al., 1995 Agundez JAG, Ledesman MC, Ladero JM; Benitez J: Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in white population. Clin Pharamacol Ther. 1995, 57, S.265-269,

Aitchison et al., 1999 Aitchison KJ, Munro J, Wright P, Smith S, Makoff AJ, Sachse C, Sham PC, Murray RM, Collier DA, Kerwin RW: Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol. 1999, 48(3), S.388-394,

Aklillu et al., 1996 Aklillu E, Bertilsson L, Johanson I, Rodrigues F, Ingelman-Sundberg M: Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996, 278, S.441-446,

Alvan et al., 1990 Alvan G, Bechtel P, Iselius L, Gundert-Remy U: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European population. Eur J Clin Pharmacol. 1990, 39, S.533-537,

Angst, 1980 Angst J: Verlauf unipolar depressiver, bipolar manisch-depressiver und schizo-affektiver Erkrankungen und Psychosen: Ergebnisse einer prospektiven Studie. Fortschr Neurol Psychiatr. 1980, 48, S.3-30,

APA Task Force on the Use of Laboratory Tests in Psychiatry, 1985 Tricyclic antidepressants-blood evel measurement and clinical outcome: an APA Task Force report. Am J Psychiary. 1985, 142, S.155-162,

Arranz et al., 2001 Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW: Application of pharmacogenetics in psychiatry: Personalisation of treatment. Exp Opin Pharmacother. 2001, 2(4), S.537-542,

Aynacioglu et al., 1999 Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Muradiye N, Schröder T, Kayaalp OS, Roots I, Brockmöller J: Low frequencies of defective alleles of cytochrome P450 enzymes2C19 and 2D6 in a Turkish population. Clin Psychopharmacol. 1999, 66, S.185-192,

Bauer et al., 2002 Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ: World Federation of Societies of Biological Psychiatry (WFSBP), Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorders. World J Biol Psychiatry. 2002, 3, S.5-43,

Baumann et al., 1986 Baumann P, Jonzier Perey M, Koeb L, Küpfer A, Tinguely D, Schopf J: Amitriptyline pharmacokinetics and clinical response: Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol. 1986, 1, S.102-112,

Baumann et al., 1998 Baumann P, Broly F, Kosel M, Eap CP: Ultrarapid metabolism of clomipramine in a therapy resistant depressive patient, as confirmed by CYP2D6 genotyping. Pharmacopsychiatry. 1998, 31(2), S.72,

Bergmann et al., 2001 Bergmann Tk, Bathum L, Brosen K: Duplication of CYP2D6 predicts high clearence of desipramine but high clearance does not predict duplication of CYP2D6. J Clin Pharmacol. 2001, 57, S.123-127,

Bertilsson et al., 1981 Bertilsson L, Mellstrom B, Sjokvist F, Martenson B, Asberg M: Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implications. Lancet. 1981, 1 (8219), S.560-561,

Bertilsson et al., 1992 Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F: Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther. 1992, 51, S.388-397,

Bertilsson, 1995 Bertilson L: Geographical/interracial differences in polymorphic drug oxidation. Clin Parmacokinet. 1995, 29, S.192-209

Bertilsson et al., 1997 Bertilsson L, Dahl ML, Tybring G: Pharmacogenetics of antidepressants: Clinical aspects. Acta Psychiatr Scan. 1997, 96(Suppl 391), S.14-21,

Bertilsson et al., 2002 Bertilsson L, Dahl MJ, Dalen P, Al-Shurbaji A: Molecular genetics of CYP2D6: Clinical focus on psychotropic drugs. Br J Clin Pharmacol. 2002, 53, S.111-122,

Bertz und Grannemann, 1997 Bertz RJ and Grannemann GR: Use of in vitro data and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997, 32, S.210-258,

Bhasker et al., 1997 Bhasker CR, Miners JO, Coulter S, Birkett DJ: Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics. 1997, 7, S.51-58,

Bird und Schwalbe, 1965 Bird ED and Schwalbe jr. FC: Prolonged hypoglycemia secondery to tolbutamide. Ann Intern Med. 1965, 62, S.110-112,

Bradford, 2002 Bradford LD: CYP2D6 allele frequency in Europea Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 3, S.229-243,

Brockmöller et al., 2000 Brockmöller J, Kirchheiner J, Meisel CH, Roots I: Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics. 2000, 2, S.125-151,

Charlier et al., 2003 Charlier C, Broly F, Lhermitte M, Pinto E, Ansseau M, Plomteux G: Polymorphism in the CYP2D6 Gene: Association with plasma concentrations of fluoxetine and paroxetine. Therapeutic Drug Monitoring. 2003, 25 (6), S.738-742,

Chen et al., 1996 Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Craig Meek Q, Neill JR, Martin WL, Hays LR, Wedlund PJ: The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcome in psychiatry. Clin Pharmacol Ther. 1996, 60, S.522-534,

Chiba K und Kobayashi K, 2000 Chiba K und Kobayashi K: Antidepressants. Hrsg.: Levy R et al. (eds): Metabolic drug interactions. Philadelphia, Lippincott, Williams and Wilkins, S.233-243,

Chou et al, 2000 Chou WH, Yan FX, De Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ: Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Pharmacol . 2000, 20, S.246-251,

Crespi und Miller, 1997 Crespi CL and Miller VP: The R144C change in the CYP2C9* 2 allele alters interaction of the cytochochrome alters interaction with NADPH: cytochrome P450 oxidoredutase. Pharmacogenetics. 1997, 7, S.203-210,

Dahl and Bertilsson, 1993 Dahl ML, Bertilsson L: Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics. 1993, 3 (2), S.61-70,

Dahl et al., 1994 Dahl ML, Tybring G, Elwin CE et al. , : Stereoselective disposition of mianserin is related to debrisoquine hydroxylation polymorphism. Clin Pharmacol Ther. 1994, 56, S.176-183,

Dahl et al., 1995 Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the mleclar genetic basis. J Pharmac Exp Ther. 1995, 274, S.516-520,

Dalén et al., 1998 Dalén P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L: 10-Hydroxylation of nortryptilene in white persons 0, 1 and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998, 63(4), S.444-452,

Daly et al., 1996a Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM: Nomenclature for human CYP2D6 alleles. Pharmacogenetics. 1996a, 6, S.193-201,

Dartnell et al., 1996 Dartnell JG, Anderson PP, Chohan V et al.: Hospitalisation for adverse events related to drug-therapy: Incidence, avoidability ans costs. Med J Aust. 1996, 164, S.695-662,

De Leon et al., 1998 De Leon J, Barhill J, Rogers T, Boyle J, Chou WH, Wedlund PJ: Pilot Study of the Cytochrome P450-2D6 Genotype in a Psychiatric State Hospital. Am J Psychiatry. 1998, 155, S.1278-1280,

De Morais et al., 1994 De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoinmetabolism in humans. J Biol Chem. 1994, 269, S.15419-15422,

De Morais et al., 1994b De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994b, 46, S.594-598,

De Vries et al., 2001 De Vries EM, Pot HJ, Conemans JMH et al.: The clinical relevance of routine genotyping of CYP2D6/2C19 null alleles of psychiatric patients. Br J Clin Pharmacol. 2001, 53, S.543-559,

De Waziers et al., 1990 De Waziers I, Cugnenc PH, Leroux JP, Beaune PH: Cytochrome P450 isoenzymes, epoxide hydroxylase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Parmacol Exp Ther. 1990, 253, S.387-393,

Desta et al., 2002 Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002, 41, S.913-958,

Donoghue and Hylan, 2004 Donoghue J and Hylan TR: Antidepressant use in clinical practice: Efficacy v. effectiveness. Br J Psychiatry. 2001, 179, S.9-17,

Eichelbaum et al., 1979 Eichelbaum M, Spannbricker N, Steincke B, Dengler HJ: Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur J Clin Pharmacol. 1979, 16, S.183-187,

Eichelbaum et al., 1987 Eichelbaum M, Bauer MP, Dengler HJ et al.: Chromosomal assignment of human cytochrome P450 (debrisoquine / sparteine type) to chromosome 22. Br J Clin Pharmacol. 1987, 23, S.455-458,

Endicott et al., 1976 Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976, 33 (6), S.766-771,

Ereshefsky et al., 1988 Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A: Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramin - new data and review. Clin Chem. 1988, 34(5), S.863-880,

Evans, 2003 Evans WE: Pharmacogenomics: Marshalling the human genome to individualize drug therapy. Gut. 2003, Suppl.2, S.10-18,

Evans und McLeod Evans WE and Mc Leod HL: Genetic polymorphisms influencing drug disposition. N Engl J Med. 2003, 348(6), S.538-549,

Fava und Davidson Fava M and Davidson KG: Definition and epidemiology of treatment-resistent depression. Psychiatr Clin North Am. 1996, 19, S.179-200,

Fava, 2003 Fava M: Diagnosis and definition of treatment-resistent depression. Biological Psychiatry. 2003, 53(8), S.649-659,

Ferguson et al., 1998 Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson G, Sarich TC, Wright JM, Dayer P, Goldstein JA: A new genetic defect in human CYP2C19: Mutation of the inition codon is responsible for poor metabolism of S-Mephenytoin. JPET. 1998, 284, S.356-361,

Frank et al., 1988 Frank E, Carpenter LL, Kupfer DJ : Sex differences in recurrent depression: Are there any that are significant?. Am. J. Psychiatry. 1988, 145, S.41-45,

Furuta et al., 1999 Furuta T, Ohashi K, Kosuge K et al.: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999, 65, S.552-561,

Gaedigk et al., 2003 Gaedigk A, Ryder DL, Bradford LD, Leeder JS: CYP2D6 Poor Metabolizer Status can be ruled out by a Single Genotyping Assay for the -1584G Promotor Polymorphism. Clin Chem.. 2003, 49, S.1008-1011,

Ghahramani et al., 1997 Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997, 43 (2), S.137-144,

Goldstein und De Morais, 1994 Goldstein JA und De Morais SM: Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994, 4, S.285-299,

Gonzalez et al., 1988 Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA: Characterization of the common genetic defect in human deficient in debrisoquine metabolism. Nature. 1988, 331, S.442-446,

Gotoh, 1992 Gotoh O: Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analysis of amino acid and coding nucleotide sequences. J Biol Chem. 1992, 267, S.83-90,

Gram, 1977 Gram LF: Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet. 1977, 2, S.237-251,

Grasmäder et al., 2004 Grasmäder K, Verwohlt PL, Rietschel M, Dragisevic A, Müller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasmaconcentration and clinical effects on antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004, 28,

Griese et al., 1997 Griese EB, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T, Eichelbaum M: Assessment of predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998, 8, S.15-26,

Grohmann et al., 1994 Grohmann R, Rüther E, Schmidt LG: Unerwünschte Wirkungen von Psychopharmaka. Ergebnisse der AMÜP-Studie. Heidelberg, Springer,

Grzesiak et al., 2003 Grzesiak M, Beszlej A, Lebioda A, Jonkisz A, Dobosz T, Kiejna A: Retrospective assessment of the antidepressant tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype. Psychiatr Pol. 2003, 37 (3), S.433-444,

Guidice et al., 1997 Guidice JM, Marez D, Sabbagh M, Legrand-Andreoletti M, Spire C, Alcaide E, Lafitte JJ, Broly F: Evidence for CYP2D6 expression in human lung. Biochem Biophys Res Commun. 1997, 241, S.79-85,

Härter et al., 2004 Härter M, Sitta P, Ferdinand K, Metzger R, Wiegand W, Schell G, Stieglitz RD, Wolfersdorf M, Felsenstein M, Berger M: Externe Qualitätssicherung bei stationärer Depressionsbehandlung . Dscht Aerztebl. 2004, 27, S.101 :A 1970-1974,

Haining et al., 1996 Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996, 333(2), S.447-458,

Helmchen, 1990 Helmchen H: Gestuftes Vorgehen bei Resistenz gegen Antidepressiva-Therapie. Hrsg.: Möller HJ: Therapieresistenz unter Antidepressiva-Behandlung. Berlin , Springer, S.237-250,

Ho et al., 2001 Ho PC, SavilleDJ, Wanwimolruk S: Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci. 2001, 4, S.217-27,

Horsmans et al., 1994 Horsmans Y, Lannes D, Pessayre D, Larrey D: Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by AtriumR, a fixed combination preparation containing phenobarbital, ferbamate and diferbamate. J Hepatol. 1994, 21, S.1075-1079,

Ingelman-Sundberg, 1999 Ingelman-Sundberg M: Duplication, multiduplication and amplification of genes encoding drug metabolizing enzymes: Evolutionary, toxicological and clinical pharmacological aspects. Drug Metabolism Reviews. 1999, 31(2), S.449-459,

Ingelman-Sunberg, 2003 Ingelman-Sundberg M: Implication of polymorphic Cytochrom P450-dependent drug metabolism for drug development. Drug Metabolism and Disposition. 2001, 29 (4), S.570-573,

Inoue et al., 1997 Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T: Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methylhydroxylation and S-mephenytoin 4`-hydroxylation activities in livers of Japanese and Caucasian population. Pharmacogenetics. 1997, 7, S.103-113,

Jacobi et al., 2004 Jacobi F, Wittchen HU, Hölting C et al. ,: Prevalence, comorbidity and correlates of mental disorders in a general population: Results from the German health interview and examination survey (GHS). Psychol Med (in press). 2004,

Johansson et al., 1996 Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M: PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics. 1996, 6, S.351-355,

Jurima et al., 1985 Jurima M, Inaba T, Kadar T, Kalow W: Genetic polymorphism of mephenytoin p( 4`)hydroxylation: Difference between Orientals and Caucasians. Br J Clin Pharmacol. 1985, 19, S.483-487,

Kaneko et al., 1999 Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, Ishizaki T, Bjorkman A: Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Infect Dis. 1999, 179, S.974-979,

Kawanishi et al., 2003 Kawanishi C, Lundgren S, Agren H, Bertilsson L: Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders. Eur J Clin Pharm. 2003,

Kessler et al., 2003 Kessler RC, Berglund P, Demler O et al. ,: The epidemiology of major depressive disorder: Results from the national comorbidity survey replication (NCS-R). JAMA. 2003, 289, S.3095-3105,

Kidd et al., 1999 Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999, 9(1), S.71-80,

Kimura et al., 1989 Kimura S, Kozak CA, Gonzalez FJ: Identification of a novel P450 expressed in rat lung: cDNA cloning and sequence, chromosome mapping and induction by 3-Methylcholanthrene. Biochemistry. 1989, 28, S.3798-3803,

Kirchheiner et al., 2001 Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjöquist F, Spina E, Brockmöller J: CYP2D6 and CYP2C19 genotype-based dose recommendation for antidepressants: a first step towards subpopulation specific dosages. Acta Psychiatr Scand . 2001, 103, S.1-21,

Kirchheinet et al., 2002 Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J: Constributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002, 12, S.571-580,

Kirchheiner et al., 2003 Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M: Individualized medicine - Implementation of pharmacogenetic diagnostic in antidepressant drug treatment of major depression. Pharmacopsychiatry. 2003, 36 (Suppl. 3), S.235-243,

Kirchheiner et al., 2004 Pharmacogenetics of antidepressants and antipsychotics :The contribution of allelic variation to the phenotype of drug response. Kirchheiner j, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I , Brockmöller J: Molecular Psychiatry. 2004, S.1-32,

Kirchheiner et al., 2004 Kirchheiner J, Heesch C, Bauer S, Meisel Ch, Seringer A, Goldammer M, Tzvetkov M, Meineke I, Roots I, Brockmöller J: Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004, 76, S.302-312

Koyama et al., 1996 Koyama E, Tanaka T, Chiba K et al., : Steady-state plasma concentrations of imipramine and desipramine relation to S-mephenytoin 4´hydroxylation status in japanese depressive patients . J Clin Psychopharmacol. 1996, 16, S.286-293,

Kornstein et al., 2000a Kornstein SG, Schatzberg AV, Thase ME, Yonkers KA, McCullen JP, Keitner GI, Gelenberg AJ, Ryan CE, Hess AL, Harrison W et al.: Gender differences in chronic major and double depression. J. Affect. Disord. 2000a, 60, S.1-11,

Kreeger, 1962 Kreeger N: Tolbutamide-induced hypoglycemia. N Engl J Med. 1962, 266, S.818-820,

Küpfer et al., 1984 Küpfer A, Desmond P, Patwardhan R, Schenker S, Branch RA: Mephenytoin hydroxylation deficiency: Kinetics after repeated doses. Clin Pharmcol Ther. 1984, 35, S.33-39,

Küpfer et al., 1984b Küpfer A, Desmond P, Patwardhan R, Schenker S, Branch RA: Mephenytoin hydroxylation deficiency: Kinetics after repeated doses. Cli Pharmacol Ther. 1984b, 35, S.33-39,

Küpfer und Preisig, 1984 Küpfer A and Preisig R: Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. J Clin Pharmacol. 1984, 26, S.753-759,

Kutt et al., 1964 Kutt H, Wolk M, MC Dowell F: Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology. 1964, 14, S.542-548,

Laine et al., 2001 Laine K, Tybring G, Hartter S, Andersson K, Svensson JO, Widen J, Bertilsson L: Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measered by nortryptiline pharmacokinetics and the debrisoquine test. Clin Pharamacol Ther. 2001, 70, S.327-35,

Laux, 1986 Laux G: Chronifizierte Depressionen. Stuttgart, Enke,

Lessard et al., 1999 Lessard E, Yessine M, Hamelin B, O`Hara G, Leblanc J, Turgeon J: Influence of CYP2D6 activity on the disposition of cardiovascular toxicity of the antidepresant agent venlavaxine in humans. Pharmacogenetics. 1999, 9, S.435-443,

Lin et al., 1995 Lin EHB, Korff M, Katon W et al.: The role of the primary care physicians in patients adherence to antidepressant therapy. Med Care. 1995, 33, S.67-74,

Linden, 1997 Linden M: Therapieresistenz und Patienten-Non-Compliance bei depressiven Störungen. Hrsg.: Bauer M, Berghöfer A: Therapieresistente Depressionen. Berlin, Springer, 1997 S.47-56,

Lindpaintner, 2003 Lindpaintner K: Pharmacogenetics and the future of medical practice. J Mol Med. 2003, 81, S.141-153,

Lovlie et al., 1996 Lovlie R, Daly AK, Molven A, Idle JR, Steen VM: Ultrarapid metabolizers of debrosoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letters. 1996, 392, S.30-34,

Lovlie et al., 2001 Lovlie R, Daly AK, Matre GE, Molven A, Steen V: Polymorphisms in CYP2D6 duplication-negative individuals with the ulrarapidmetabolizer phenotype: A role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics. 2001, 11 (1), S.45-55,

Mahgoub et al., 1977 Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977, 2(8038), S.584-586,

Malhotra et al., 2004 Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of Psychotropic Drug Response. Am J Psychiatry. 2004, 161, S.780-796,

Manji et al., 2003 Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, N AG, Zarate CA, Jr., Charney DS: Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003, 53, S.707-742,

Marchioni et al., 1996 Marchioni E, Perucca E, Soragna D, Bo P, Malaspina A, Ferrandi D, Albergati A, Savoldi F: Choreiform sydrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. Neurology. 1996, 46, S.853,

Marez et al., 1997 Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Lafitte JJ et al.: Polymorphism of the cytochrome P450 CYP2D6 in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997, 7, S.193-202,

McDonald et al., 2002 McDonald HP, Garg AX, Haynes RB: Interventions to enhance patient adherence to medication prescriptions: Scientific review. Jama. 2002, 288, S.2868-2879,

McElroy et al., 2000 McElroy S, Richmond J, Lira M, Friedman D, Silber BM, Milos PM: CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS Pharmsci. 2000, 2(4), S.Art.33,

Meier et al., 1985 Meier UT, Kronbach T, Meyer UA: Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem. 1985, 151, S.286-291,

Meisel et al., 2000 Meisel CH, Roots I, Cascorbi I, Brinkmann U, Brockmöller J: How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med. 2000, 38(9), S.869-876,

Meyer, 1994 Meyer UA: The molecular basis of genetic polymorphism of drug metabolism. J Pharm. 1994, 46, S.409-415,

Mihara et al., 1997 The CYP2D6 genotype and plasma concentration of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. Mihara K, Otani K, Tybring G, Dahl ML, Bertilsson L, Kaneko S : Clin Psychopharmacol. 1997, 17, S.467-471,

Miners und Birkett, 1998 Miners JO and Birkett DJ: Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. BR J Clin Pharm. 1998, 45, S.525-538,

Möller, 1997 Möller HJ: Therapieresistenz unter Antidepressiva-Therapie: Definition, Epidemiologie und Risikofaktoren. Hrsg.: Bauer M, Berghöfer A: Therapieresistente Depressionen. Berlin, Springer, 1997 S.3-15,

Möller, Laux, Kampfhammer, 2002 Möller HJ, Laux G, Kampfhammer HP: Psychiatrie und Psychotherapie. 2.Auflage Berlin, Springer, 2002 S.1201,

Moltke et al., 1997 Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Wrights CE, Harmatz JS, Shader RI: Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology. 1997, 132(4), S.402-407,

Moore et al., 1998 Moore N, Lecointre D, Noblet C and Mabille M: Frequency and costs od serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998, 45 (3), S.301-308,

Morinobu et al., 1997 Morinobu S, Tanaka K, Kawakatsu S et al. ,: Effects of genetic defects in the CYP2C19 gene on the N-demethylation of impramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci. 1997, 51, S.253-257,

Müller et al., 2003 Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmäder K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C: Therapeutic drug monitoring of tricyclic antidepresants: How does it work under clinical conditions. Pharmacopsychiatry. 2003, 36, S.98-104,

Murphy et al., 2001 Murphy GM Jr, Polock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH, Reynolds CF: CYP2D6 genotyping with olinucleotides microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology. 2001, 25, S.737-743,

Murphy et al., 2003 Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF: Pharmacogenetics of Antidepressant Medication Intolerance. Am J Psychiatry. 2003, 160, S.1830-1835,

Murray, 1997 Murray CJ, Lopez AD: Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997, 349, S.1436-1442,

Nakamura et al., 1985 Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian population. Clin Pharmacol. 1985, 38, S.402-408,

Nebert et al., 1987 Nebert DW, Jaiswal AK, Meyer UA, Gonzalez FJ: Human P450 genes: evolution, regulation, and possible role in carcinogesis. Biochem Soc Trans. 1987, 15, S.586-589,

Nebert, 1999 Nebert DW: Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist ?. Clin Genet. 1999, 56, S.247-258,

Nebert, 2000 Nebert DW: Drug-metabolizing enzymes, polymorphisms and interindividual response to enviromental toxicants. Clin Chem Lab Med. 2000, 38(9), S.857-861,

Nelson, 2003 Nelson JC: Managing treatment-resistent major depression. J Clin Psychiatry. 2003, 64 Suppl 1, S.5-12,

Perry et al., 1987 Perry PJ, Pfohl MB, Holstad SG: The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: A retrospective analysis of literature using logistic regression analysis. Clin Pharmacokinet. 1987, 13(6), S.381-392,

Perucca et al., 1997 Perucca E, Marchioni E, Soragna D, Savoldi F: Fluoxetine-induced movement disorders and deficient CYP2D6 enzyme activity. Mov Disord. 1997, 12 (4), S.624-625,

Perugi et al., 1990 Perugi G, Musetti L, Simonini E, Piagentini F, Cassano GB, Akiskal HS, : Gender-mediated clinical features of depressive illness: The importance of temperamental differences. Br. J. Psychiatry. 1990, 157, S.835-841,

Preskorn et al., 1993 Preskorn SH, Burke MJ, Fast GA: Therapeutic drug monitoring: Principles and practice. Psychiatr Clin North Am. 1993, 16, S.611-645,

Rabkin und Klein, 1987 Rabkin J, Klein D: The clinical measurement of depressive disorders. Band The measurement of depression. New York: Guilford, S.30-83,

Raimundo et al., 2000 Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM: Eludication of the genetic basis of the common "intermediate metabolizer" phenotype for drug oxidation by CYP2D6. Pharmacogenetics. 2000, 10 (7), S.577-581,

Rane et al., 1996 Rane A, Liu Z, Bjelfman C, Thyr C, Ericson H, Hansson T, Hendersson C, Wolf CR: Differencial effects of neuroleptic agents on hepatic cytochrome P-450 isoenzymes in the male rat. Biochem Biophys Acta. 1996, 1291, S.60-66,

Rao et al., 1996 Rao ML, Ruhrmann S, Retey B et al.: Low plasma thyroid indices of depressed patients are attenuated by antidepressant drugs and influence treatment outcome. Pharmcopsychiatry. 1996, 29, S.180-186,

Rao et al., 1999 Zur klinischen Relevanz von Paroxetin-Serumkonzentrationen. Rao ML, Bagli M, Papassotiropoulos A, Sobanski A, Deister A: Psychopharmakotherapie. 1999, 6, S.158-160,

Rau et al., 2004 Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T: CYP2D6 genotype: Impact on adverse affects and nonresponding during treatment with antidepressants- A pilot study. Clin Pharmacol Ther. 2004, 75 (5), S.386-393,

Rendic and Di Carlo, 1997 Rendic S, Di Carlo FJ: Human-cytochrome P450 enzymes. A status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev. 1997, 29 (1-2), S.413-580,

Rigal et al., 1987 Rigal JG, Albin AC, Duchier AR, D`Aulnay JM, Fenelon JH, Vincon GA, Demots-Mainard FM: Imipramine blood levels and clinical outcome. J Clin Psychopharmacol. 1987, 7(4), S.222-229,

Ring et al., 2001 Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, Vandenbraden M, Wrighton SA: Identifikation of the human cytochrome P450 responsible for in vitro formation of R-and S-norfluoxetine. J Pharmacol Exp Ther. 2001, 297, S.1044-1050,

Roberts et al., 2004 Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA: No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine and nortriptilyne. Hum Psychopharmacol Clin Exp. 2004, 19, S.17-23,

Sachse et al., 1997 Sachse C, Brockmöller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Human Genet. 1997, 60, S.284-295,

Sallee et al., 2000 Sallee FR, DeVane CL, Ferrel RE: Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol. 2000, 10 (1), S.27-34,

Scheibe et al., 2003 Scheibe S, Preuschof C, Cristi C, Bagby RM: Are there gender differences in major depression and its response to antidepressants?. Journal of affective disorders. 2003, 75, S.223-235,

Schmitz und Drobnik, 2003 Schmitz G und Drobnik W: Genpolymorphismen und interindividuelles Risiko der Pharmakotherapie. Klinikarzt. 2003, 32(1), S.23-27,

Scordo et al., 2004 Scordo MG, Caputi AP, D`Arrigo C, Fava G, Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res. 2004, 50 (2), S.195-200,

Seretti et al ., 2002 Seretti A, Lilli R, Smeraldi E: Pharmacogenetics in affective disorders. European Journal of Pharmacology. 2002, 438, S.117-128,

Setiabudy et al., 1992 Setiabudy R, Chiba K, Kusaka M, Ishizaki T: Caution in the use of a 100mg dose of racemic mephenytoin for phenotyping Southeastern Oriental Subjects. Br J Clin Pharmacol. 1992, 33, S.665-666,

Shimada et al., 1994 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994, 270, S.414-423,

Sindrup et al., 1992 Sindrup SH, Brosen K, Gram LF: The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992, 51, S.278-287,

Skjelbo et al., 1996 Skjelbo E, Mutabingwa TK, Bygbjerg I, Nielsen KK, Gram LF: Chlorguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther. 1996, 59, S.302-311,

Sorensen, 2002 Sorensen JM: Herb-drug, food-drug, nutrient-drug and drug-drug interactions: Mechanism involved and their medical applications. J Altern Complement Med. 2002, 8(3), S.293-308,

Spina et al., 1997 Spina E., Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E: Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study. Eur J Clin Pharmacol. 1997, 51, S.395-398,

Steen et al., 1995 Steen VM, Andreassen, OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK: Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995, 5, S.215-223,

Steimer et al., 2004 Steimer W, Zöpf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S: Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentration of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clinical Chem. 50(9), S.1623-1633

Steward et al., 1997 Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997, 7(5), S.361-367,

Stubbins et al., 1996 Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR: Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996, 6, S.429-439,

Sullivan-Klose et al., 1995 Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminski LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996, 6 (4), S.341-349,

Swanson et al., 1997 Swanson JR, Jones GR, Krasselt W, Denmark LN, Ratti F: Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: A review of the literature and possible mechanisms. J Forensic Sci. 1997, 42 (2), S.335-339,

Task Force Laboratory Tests in Psychiatry Task Force on the use of Laboratory Tests in Psychiatry: Tricyclic antidepressant-blood level measurement and clinical outcome. Am J Psychiatry. 1995, 142, S.155-162,

Thase, 2003 Thase ME: New approaches to managing difficult-to-treat depressions. J Clin Psychiatry. 2003, 64(Suppl 1), S.3-4,

Tyndale et al., 1991a Tyndale RF, Sunahara R, Inaba T, kalow W, Gonzalez FJ, Niznik HB: Neuronal cytochrome P4502D1 (debrisoquine / sparteine type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991a, 40, S.63-68,

Vandel et al., 1999 Vandel P, Haffen E, Vandel S, Bonin B, Nezelof S, Sechter D, Broly F, Bizouard P, Dalery J: Drug extrapyramidal side effects: CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol. 1999, 55 (9), S.659-665,

Veronese et al., 1993 Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA, Birkett DJ: Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J. 1993, 289, S.533-538,

Vormfelde et al., 1997 Vormfelde SV, Bitsch A, Meinike I, Gundert-Remy UM, Gleiter CH: Non-response to maprotiline caused by ultra-rapid metabolism that is different fom CYP2D6? Eur J Clin Pharmacol. 1997, 52(5), S.387-90,

Wedlund, 2000 Wedlund PJ: The CYP2C19 enzyme polymorphism. Pharmacology. 2000, 61, S.174-183

Wedlund, 2004 Wedlund PJ, De Leon J: Cytochrom P450 2D6 and antidepressant toxicity and response: What is the evidence. Clin Pharamcol Ther. 2004, 75 (5), S.373-375,

Wilkinson et al., 1989 Wilkinson GR, Guengerich FP, Branch RA: Genetic polykmorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989, 43, S.53-76,

Wittchen Wittchen HU: Epidemiology of affective disorders. Band Contemporary Psychiatry. Heidelberg, Springer, S.331-341,

Wittchen und Unland, 1991 Wittchen HU, Unland H: Neue Ansätze zur Symptomerfassung und Diagnosestellung nach ICD-10 und DSM-III-R: Strukturierte und standardisierte Interviews. Zeitschrift für klinische Psychologie. 1991, 4, S.321-342,

Wolf und Smith, 1999 Wolf CR and Smith G: Pharmacogenetics. Br Med Bull. 1999, 55(2), S.66-386,

Wrighton und Stevens, 1992 Wrighton SA and Stevens JC: The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol. 1992, 22(1), S.1-21,

Wrighton et al., 1993 Wrighton SA, Stevens JC, Becker GW, van den Branden M: Isolation and characterization of human liver cytochrome P4502C19: Correlation between 2C19 and S-mephenytoin-4`-hydroxylation. Arch Biochem Biophys. 1993, 306, S.240-245,

Xie et al., 1999 Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ: Allelic, genotypic and phenotypic distributions of S-mephenytoin-4`-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacognetics. 1999, 9(5), S.539-549,

Zanger et al., 2001 Zanger UM, Fischer J, Raimundo S, Stuven T, Evert BO, Schwab M et al.: Comprehensive analysis of the genetic factors determining expresion and function of the hepatic CYP2D6. Pharmacogenetics. 2001, 11, S.573-585,

Webseiten

http://drnelson.utmem.edu/CytochromeP450.html; UT Memphis, Department Of Biochemistry 1993: Cytochrome P450 homepage.

http://www.imm.ki.se/CYPalleles/default.htm; Karolinska Institutet National Institute Of Environmental Medicine 1999: Human cytochrome P450 (CYP) allele nomenclature committee.

http://medicine.iupui.edu/flockhart/; UT Indiana, Department Of Medicine 2002: Cytochrome P450 drug interaction table.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
30.11.2005